FLGT — Fulgent Genetics, Inc.

Summary of Fulgent Genetics Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $71.1 million, down 3.2% year-over-year and 14.6% quarter-over-quarter.
• Precision Diagnostics Revenue: $40.2 million (down 8.8% YoY, down 16.5% QoQ).
• Anatomic Pathology Revenue: $25.1 million (down 0.9% YoY, down 7.2% QoQ).
• Biopharma Services Revenue: $5.8 million (up 43.2% YoY, down 28.0% QoQ).
• GAAP Gross Margin: 30.2%; Non-GAAP Gross Margin: 32.3%.
• GAAP Operating Expenses: $56.1 million, down from $68.8 million in the previous quarter.
• GAAP Loss: $24.8 million, or $0.08 per share.
• Adjusted EBITDA: Loss of approximately $15.2 million.
• Cash Position: $604.7 million at quarter-end, down $100.8 million from the previous quarter due to acquisitions and stock repurchases.

2. Strategic Updates and Business Highlights:

• Completed acquisitions of Bako Diagnostics and StrataDx, contributing $2.6 million in revenue for the quarter.
• Investments in AI and digital pathology are expected to enhance growth and operational efficiency.
• Progress in therapeutic development with FID-007 advancing through Phase II trials and FID-022 in Phase I dose escalation.
• New product launches, including a whole genome test integrated with Illumina's TruPath technology and advancements in pharmacogenomic testing.

3. Forward Guidance and Outlook:

• Reiterated total revenue guidance for 2026 at $350 million, representing an 8.5% year-over-year growth.
• Expected improvements in gross margins to approximately 39% for the full year, with further increases anticipated by year-end.
• Non-GAAP EPS guidance adjusted to a loss of $1.59 per share, reflecting a decrease in the share count due to stock repurchases.
• Anticipated revenue growth in the second half of the year, partially offsetting declines from the largest customer transitioning testing in-house.

4. Bad News, Challenges, or Points of Concern:

• Revenue decline attributed to a significant decrease in volume from the largest customer, expected to continue impacting Q2.
• Gross margins were lower than anticipated due to reduced revenues and operational challenges, including claims processing backlogs.
• The company faces risks related to the integration of acquired businesses and the potential impact of regulatory changes, such as the CMS CRUSH initiative.

5. Notable Q&A Insights:

• Management confirmed that underlying growth in Precision Diagnostics remains positive when excluding the largest customer’s impact.
• There are expectations for Q2 revenue to exceed Q1 due to the full contribution from recent acquisitions and improved base business performance.
• Discussions around FID-007 highlighted the potential for partnerships and the importance of presenting strong data at ASCO to attract collaboration opportunities.
• Management emphasized the importance of maintaining a strong cash position while pursuing strategic investments and operational improvements.

Overall, Fulgent Genetics reported a challenging quarter with revenue declines primarily driven by customer transitions while maintaining a focus on strategic growth initiatives and long-term investments in R&D and sales capabilities.